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BACKGROUND: Antiretroviral therapy is a proven medication 
given for Human Immunodeficiency Virus positive individuals. 
However, first-line antiretroviral treatment failure becomes a 
public health issue and early detection of treatment failure is 
crucial for timely actions. Therefore, this study aimed to identify 
the predictors of time to first-line antiretroviral treatment failure 
among adult patients living with HIV in public health facilities of 
Arba Minch Town.  
METHODS: Institution-based retrospective cohort study was 
employed among 396 adult patients that were selected using simple 
random sampling. The data on relevant variables were extracted 
from patient medical cards. Bi-variable and multi-variable Cox 
proportional hazard regression analyses were used to identify 
predictors.  
RESULTS: The median survival time was 21 months. Substance 
use (AHR=2.94, 95% CI=1.62 to 5.32), disclosure status 
(AHR=1.98, 95% CI=1.03 to 3.79), time since HIV diagnosis 
(AHR=2.19 95% CI=1.01 to 4.79), WHO clinical stage 
(AHR=2.02, 95% CI=1.02 to 4.00), opportunistic infection 
(AHR=2.27, 95% CI=1.23 to 4.19), nutritional status (AHR=3.78, 
95% CI=1.99 to 7.17), functional status (AHR=2.71 95% CI=1.33 
to 5.51), CD4 count (AHR=1.99, 95% CI=1.05 to 3.75), and 
adherence level (AHR=1.99, 95% CI=1.05 to 3.76) were 
independent predictors of time to first line ART treatment failure. 
CONCLUSION: History of substance use, lack of disclosure 
status, time since HIV diagnosis, advanced WHO clinical staging, 
low CD4 counts, opportunistic infection, functional status, poor 
adherence to ART and under-nutrition affect the time to first-line 
treatment failure among adult patients living with HIV. Therefore, 
preventive interventions, and information and counseling focusing 
on high risk groups of HIV infected adult are very important.  
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Human Immunodeficiency Virus (HIV) infection 
continues to be one of the public health issues 
(1,2). Worldwide, approximately 36.7 million 
people were living with HIV/AIDS at the end of 
2016 (3). Sub-Saharan Africa is the most affected 
region, with nearly 1  in every 25 adults living 
with HIV (3). In Ethiopia, a total of 718,500 
people were living with HIV/AIDS at the end of 
2016, and adult HIV prevalence was estimated 
1.1% (4,5).  
To tackle this problem, new global efforts 
brought that the number of people receiving HIV 
treatment increased dramatically in recent years, 
particularly in resource-poor countries (3). 
Among resource-poor countries, Ethiopia has 
achieved a significant success in scaling up anti-
retroviral therapy (ART) services since 2005 (5).  
Effective ART is usually convoyed by an 
increase in the number of CD4+ T - cells and the 
functional restoration of patents’ immune 
responses and decline in HIV viral load. 
However, the requirement of regular and lifelong 
medication of HIV patients is challenged with 
emergencies of treatment failure (2,5). 
First line ART failure enhances drug toxicity 
and drug resistance which are associated with 
high risk to transmission of drug resistant virus, 
increase in treatment complexity, worsening 
morbidity and mortality in HIV/AIDS adults. In 
addition, 46% of HIV infected patients with first 
line ART failure have higher probability to fail 
again for second-line drug and ultimately, failure 
of the HIV treatment program (6 - 8).  
Studies assessing immunological failure 
from ART initiation to occurrence of 
immunological failure found that median duration 
of treatment failure was 36 month (9). Moreover, 
another finding which assessed virologic failure 
from ART initiation to occurrence of virologic 
failure found that median survival time was 25.9 
months to 37 months (10,11) .  
To clearly understand how these time to 
treatment failures vary and to offer rigorous care 
for those at risk of treatment failure, 
understanding the  factors that are associated with 
time to first line treatment failure is very crucial. 
Furthermore, it will improve the antiretroviral 
drug resistance and increase durability of first line 
ART treatment (7,12).  
There have been different studies that tried 
to reveal different factors associated with time to  
first line  treatment failure among adult ART 
users. For instance, WHO clinical stage (13,14), 
CD4 count (6,7,15), co-infection with 
tuberculosis (8,16,17), sex of clients (14,15,18) 
and adherence to therapy (10,16,17) are the major 
predictors of time to first line ART failure. 
However, as far as our search engine was 
concerned, variables like baseline regimen, body 
weight, lack of disclosure of HIV status to the 
family members, time since HIV diagnosis and 
history of substance use were not well explored. 
Therefore, this study aimed to identify predictors 
of time to first line antiretroviral treatment failure 
among adult people living with HIV in public 
health facilities of Arba Minch Town by 
incorporating these very important variables. 
MATERIALS AND METHODS 
 
Study setting, design and participants: An 
institutional-based retrospective cohort study was 
conducted from February to March, 2018, among 
adults enrolled on first line ART between January 
01, 2013 and December 30, 2017 in Public Health 
Facilities of Arba Minch Town. The study 
included patients (aged ≥15 years) who had 
follow-up for at least 6 months after starting first 
line antiretroviral treatment.  Pregnant women, 
patients who started ART at another site and 
incomplete recording of baseline data for the 
study were excluded. 
Sample size determination and sampling 
technique: The required sample size for this 
study was calculated based on double population 
proportion formula. TB co-infection at ART 
initiation was used as the most significant 
predictor of time to first line ART failure from 
the study by Haile at Bale Zone Hospitals and the 
following assumptions were considered (16). The 
proportion of patients with TB co-infection at 
ART initiation among adult who failed first line 
ART (exposed group) was 12.1% and proportion 
of patients without TB co-infection at ART 
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initiation among adult who failed first line ART 
(non-exposed group) was 3.95%; and 95% CI, 
power of 80%, AHR of 3.06, ratio of one to one 
were used. Using Epi-Info-7.2 StatCalc the 
calculated sample size was 396. 
Simple random sampling technique was used 
to select study participants. From one hospital and 
one health center of Arba Minch Town, adult 
HIV patients on ART for ≥6 months and enrolled 
between January 01, 2013 and December 30, 
2017, were selected. Then, each adult on first line 
ART in selected health facilities with complete 
recording of baseline data for the study was 
identified, and corresponding card identification 
number was given to develop sampling frame. 
Then, study subjects were proportionally 
allocated to each selected health facility. Then the 
tudy participant were selected using simple 
random sampling techniques. 
Data collection procedures and measurements: 
The standard data extraction tool was prepared in 
English language for recording information from 
patients’ cards. This form was developed using 
the revised 2017 Federal Ministry of Health 
patient card, ART intake forms, HIV care follow-
up and further modified  by using different peer 
reviewed published literatures (7,12,16, 19).  
Treatment failure was measured either by 
clinical failure (which occurred when there was a 
new or recurrent WHO stage 3 or 4 condition) or 
immunological failure (occurred when CD4 count 
fell from baseline (below) or 50% fall of absolute 
CD4 count from the on-treatment peak value or 
persistent CD4 levels below 100 cells/mm3) or 
virological failure (occurred when plasma VL > 
1000 copied/ml) (20). 
The time to treatment failure after starting 
first line ART was calculated in months using the 
time between dates of treatment initiation to date 
of event (treatment failure) or date of 
censored.The starting point for this study was 
from initiation of ART between January 01, 2013 
to December 30, 2017 and the endpoint was  
either treatment failure, death, loss to follow-up, 
transfer to another health institution and alive up 
to end of the study without developing treatment 
failure. 
Data were collected by 6 health professionals 
and supervised by 2 health professionals who 
were trained in comprehensive HIV care to 
ensure the quality of data. The data were 
collected by reviewing the patients’ medical 
cards.The missed data from patients’ medical 
records were cross checked with ART electronic 
database. The most recent laboratory results 
before starting ART were used as a base line 
value.  
Data processing and analysis: After data 
collection, each questionnaire was checked for 
completeness and consistency. Data were 
cleaned, edited, coded and entered into EPI-Data 
version 3.1 and exported to STATA version 11 
for analysis. Descriptive statistical metods like 
median, inter-quartile rage, mean, standard 
deviation and proportions were used to describe 
socio-demographic, baseline clinical related and 
follow-up characteristics of cohorts. Kaplan 
Meier survival curve was used to describe time to 
treatment failure from initiation of antiretroviral 
therapy. Both bi-variable and multi-variable Cox 
proportional hazard regression models were used 
to assess independent predictors of time to first 
line ART treatment failure. Variables with p-
value ≤0.25 in the bivariable Cox proportional 
hazards model were entered into the multi-
variable Cox proportional hazards model analysis 
to identify independent predictors of time to first 
line treatment failure. 
A p-value less than 0.05 was used to include 
a variable in the final model. The crude and 
adjusted hazard ratios together with their 
corresponding 95% confidence intervals were 
computed and interpreted accordingly.  
 
Data quality assurance: To assure the quality of 
data, different mechanisms were used including 
pre-testing of the data extraction checklist on 5% 
sample size, careful design of data extraction 
formats, using appropriate recruitment of data 
collectors and giving adequate training and 
follow-up for data collectors and supervisors.  
Ethical statement: Ethical clearance was 
obtained from the IRB of Arba Minch University, 
College of Medicine and Health Sciences. 
Personal identifiers were excluded during data 
extraction; codes were used instead. Because the 
study was being conducted on secondary data, 
obtaining informed consents from the participants 
was not possible.  
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Socio-demographic characteristics: A total of 
396 adult patients receiving ART treatment from 
December 2013 to January2017 were enrolled in 
the study. Of these, 297(75%) were from hospital 
and 99(25%) were from health center. Two 
hundred and three (51.3%) participants were 
followed ART treatment for more than 12 months 
(Table 1). 
 
Table 1: Baseline socio demographic characteristics of adult enrolled on first line ART at Public Health 
facilities of Arba Minch Town, Gamo Gofa Zone, Southern, Ethiopia, 2018 
 
Variables Frequency (n) Percent (%) 
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Table 1 Continued….. 
   




































*Adventist, Gova** Konso, Gurage,Slite, Tigre 
 
Baseline clinical characteristics: At baseline, 
146(36.9%) of the participants were found on 
WHO stage I. Almost half of the study 
participants, 203(51.3%), had initial CD4 count 
≥200cells/mm3. The median baseline of CD4 
counts was 192.5 cell/mm3 with inter-quartile 
ranges of 93.5, 317.5. About three hundred and 
forty-five (77.0%) were working in their 
functional status at the time of enrollment. Of the 
study participants, 98(24.8%) had history of 
opportunistic infections while 27(27.6%) of them 
had TB co-infection at initiation of ART. 
 
Baseline chemoprophylaxis characteristics: 
About two hundred forty-one (60.9%) took 
Cotrimoxazole preventive therapy (CPT) while 
two and hundred sixty-four (66.7%) were taking 
Isoniazid preventive therapy (ITP) at the time of 
enrollment. The majority (68.2%) of the study 
participants had good drug adherence followed by 
fair adherence (17.2%). Of the participants, 
343(86.6%) had no drug substitution, but sixty-
nine (17.4%) failed their initial regimen. The 
immunologic, clinical and virologic failures were 
28(40.6%), 14(20.3%) and 5(7.25%) respectively. 
There were 6(8.69%) participants with both 
virological and immunological failures and 
7(10.14%) participants with immunological and 
clinical failures. The number of participants who 
failed both virologically and clinically was 6 
(8.69%) while 3(4.35%) participants were failed 
clinically, immunologically and virologically. 
 
Time to first line antiretroviral treatment 
failure: The study participants had a median 
follow-up period of 10 months (IQR: 7.00 – 
26.75). At the end of follow-up, 69(17.42%) 
developed the event (first line antiretroviral 
treatment failure), and 327(82.58%) patients were 
censored observations. The overall median 
survival time (the expected time to event) was 21 
months with 95% CI (18, 24) (Table 2). 
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Table 2: Medians survival times for groups of different variables among adult on first line ART in public 







Std. Error of 
the Median 
95% CI of the Median 
Lower bound Upper bound   
Type of health facilities     
Hospital 
Health center 
19 1.39 16 24 
23 1.12 12 39 
Sex     
Male 
Female 
21 1.89 18 30 
18 1.98 12 26 
Residence     
Urban 
Rural 
20 1.89 16 24 
21 1.65 15 37 
Disclosure status     
Disclosed 
Not disclosed 
24 1.40 18 30 
18 1.32 15 24 
Substance use     
Yes 
No 
18 1.53 12 27 
23 1.85 18 31 
Time since HIV diagnosis     
≤3 Years 
>3Years 
18 1.03 14 23 
24 3.29 19 42 
Duration on ART (months)     
<12 
≥12 
9 0.28 7 11 
24 2.41 20 31 
Baseline WHO clinical  stage     
Mild WHO stage 
Advance stage 
24 3.50 16 33 
20 1.40 15 24 
Past OI before HARRT initiation     
Yes 
No 
17 0.56 12 23 
24 0.58 20 33 
Baseline weight     
≥ 50 Kg 
< 50 Kg 
23 2.54 8 35 
20 2.24 18 24 
Baseline BMI     
<18.5 
≥18.5 
19 2.34 12 24 
24 1.75 18 35 




23 1.94 12 30 
36 3.84 18 44 
18 1.49 12 24 
Baseline  CD4 Count     
≥200cells/mm3 
<200 cells/mm3 
24 1.05 19 36 
18 1.55 14 23 
Cotrimoxazole preventive therapy     
Yes 
No 
24 2.99 18 36 
18 0.49 14 21 
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Table 2 continued… 
Isoniazid preventive therapy     
Yes 
No 
19 2.52 15 27 
21 1.62 17 30 




24 2.01 19 43 
20 1.68 14 27 
18 0.39 12 21 
Initial regimen  substitution     
Yes 
No 
23 2.16 17 30 
20 1.7 14 24 
First line regimen started     
Nevirapine based 
Efavirenz based 
24 3.03 17 39 
20 1.29 15 24 
 
Comparison of survival curves: The Log rank 
test showed that there were significant differences 
in survival times between the different categories 
of history of substance use (p<0.001), time since 
HIV diagnosis (p<0.001), duration on ART 
(p<0.002), under nutrition (low BMI<18Kg/m2) 
at the start of ART (p<0.001), opportunistic 
infection at the start of ART (p<0.002), low 
baseline CD4 count <200cells/mm3 (p<0.0004) 
and history of regimen substitution (p<0.001) 
(Figure 1 and 2). 
 
  
Figure 1: Kaplan- Meier estimates for body mass index and history of substance use at initiation of first line ART 
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Figure 2: Kaplan- Meier estimates for time since HIV diagnosis and history of regimen substation at initiation of first 
line ART among adult in public health facilities of Arba Minch Town, Southern Ethiopia, 2018 
 
Predictors of time to first line antiretroviral 
treatment failure: In the bi-variable analysis of 
the covariates of sex, educational status, history 
of substance use, year since HIV diagnosis, 
duration on ART, disclosure status, baseline 
weight, under nutrition at baseline, low CD4 
counts of <200 cells/mm3 at baseline, advanced 
WHO staging at baseline, baseline functional 
status, history of opportunistic infection at 
initiation of ART, adherence to ART and initial 
regimen substitution were statistically significant 
at 25% level of significance; they were candidates 
for multi-variable analysis (Table 3). 
During multi-variable Cox regression 
analysis, history of substance use, lack of 
disclosure status, time since HIV diagnosis, low 
CD4 counts, opportunistic infection, bedridden 
functional status, poor adherence to ART and 
under-nutrition were found to be independent 
predictors of time to first line antiretroviral 
therapy among adult HIV infected patients after 
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Table 3: Bi-variable and multi-variable Cox proportional hazard analysis for predictors of time to first line 
antiretroviral treatment failure among adult people living with HIV in public health facilities of Arba 
Minch Town, Southern Ethiopia, 2018. 
 
 
Co-variates CHR (95% CI)  AHR (95% CI) p –values 
Sex    
Male 
Female 
1.39(0.85,2.28) 0.99 (0.57,1.74) 0.994 
1   
Educational status    
No education 
Primary education  
Secondary education 
Tertiary education 
0.67(0.36,1.23)* 1.26 (0.31, 5.05) 0.747 
1.61(1.02,2.54)* 1.41 (0.4, 4.99) 0.59 
1.44(0.96,2.16)* 1.42 (0.42,4.81) 0.58 
1   
Duration on ART (months)    
<12 
≥12 
1.33(1.03,17) 0.94 (0.52,1.68) 0.824 
1   
Disclosure status    
Disclosed  
Not disclosed  
1   
2.62(1.49,4.62)* 1.98 (1.03,3.79) 0.04** 
History of Substance used    
Yes 
No 
1.76(1.05,2.95)* 2.94 (1.62, 5.32) 0.001** 
1   
Time since HIV diagnosis (Years)    
≤3 Years 
>3Years 
2.15(1.56,2.97)* 2.19 (1.01,4.79) 0.05** 
1   
Baseline WHO clinical  stage    
Stage I or II 
Stage III or IV 
1   
1.45(0.89,2.34)* 2.02 (1.02,4.00) 0.045** 




1   
1.61(0.87,2.98)* 1.04 (0.49,2.19) 0.927 
4.31(2.49,7.44)* 2.71 (1.33,5.51) 0.006** 
History of  OI at baseline    
Yes 
No 
1.72(1.06,2.78) 2.37 (1.23,4.19) 0.009** 
1   
Baseline Weight (kg)     
≥ 50 
< 50 
0.85(0.64,1.12)* 0.64 (0.32,1.28) 0.25 
1   
Baseline BMI(Kg/m2)    
<18.5 
≥18.5 
3.11(1.92,5.04)* 3.78 (1.99,7.17) 0.001** 
1   
Baseline CD4 Count     
≥200cells/mm3 
<200 cells/mm3 
1   
2.36(1.44,3.86) 1.99 (1.05,3.75) 0.034** 




1   
2.02(1.09,3.73)* 1.26 (0.62,2.56) 0.52 
2.12(1.22,3.68)* 1.99 (1.05,3.76) 0.035** 
History of initial regimen  substitution    
Yes 
No 
2.15(1.69,2.74)* 1.26 (0.93,1.69) 0.140 
1   
Note: Baseline refers to indicators at ART initiation, *p<0.25 which are candidate for multi-variable Cox regression 
model, **p-value ≤ 0.05 statistically significant, 1 indicate reference group, CI = confidence interval 
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This study reveal that the overall median survival 
time was 21 months. This finding is in line with 
studies conducted in the University of Gondar 
Teaching Hospital, Northwest Ethiopia [17.5 
months (95% CI = 8 - 36)] and in Southern 
Ethiopia (12, 18). However, this finding is lower 
than the finding in private health facilities in 
Addis Ababa, Ethiopia [49 months (95% CI = 48 
- 51)] and in Zewditu Memorial Hospital, 
Ethiopia [53.54 months (95% CI = 40.54 - 
55.46)] (21, 22). These differences could be due 
to the difference in the diagnostic criteria for 
treatment failure, differences in follow-up periods 
and the type of first line regimen used.  
In this study, opportunistic infection at 
initiation of ART was one of the predictors that 
had a significant effect on time to first line 
antiretroviral treatment failure. This finding was 
in line with studies conduct in Southeastern 
Ethiopia and Zewditu Memorial Hospital, central 
Ethiopia (13, 22). This may be explained by the 
occurrence of opportunistic infections during 
ART which has multiple effects including pill 
burden, drug-drug interaction and overlapping 
toxicities which influence adherence (23). 
The result from this study revealed that the 
time since HIV diagnosis was an important 
determinant of treatment failure. Patients, who 
were alive since HIV diagnosis for a longer 
period, appeared to have low risk of treatment 
failure. This finding is consistent with a study 
done in Addis Ababa, Ethiopia, in which those 
who had been less than three years old since HIV 
diagnosis had 13.87 times more hazards towards 
treatment failure as compared to more than three 
years (21).This might be due to low adherence of 
patients at early stage to their drug as a result of 
lack of awareness, lack of adequate support and 
acceptance of people living with HIV.  
Regarding disclosure status, patients who did 
not disclose their HIV status to their family 
members were more likely to have treatment 
failure than those who disclosed it (AHR=1.98, 
95% CI=1.03 to 3.79, P=0.04). This finding was 
in agreement with the findings of studies 
conducted in private health facilities in Addis 
Ababa and Zewditu Memorial Hospital, central 
Ethiopia (21, 22). This might be due to the fact 
that being disclosed their status might reduce 
anxiety and improve adherence to  ART.  
This study found that low baseline CD4 
count below 200cells/mm3 at the start of first line 
ART increased the risk of developing treatment 
failure by nearly 2 times as compared to a CD4 
count ≥200 cells/mm3 (AHR=1.99, 95% CI=1.05 
to 3.75, P=0.034). Similarly, the studies 
conducted in the University of Gondar Teaching 
Hospital, Ethiopia and Chiang Mai University 
Hospital, Thailand, showed that lower baseline 
CD4 cell count was one of the main predictors of 
first line ART treatment failure (12,17). This 
might be due to the fact that patients with low 
baseline CD4 cell count have lesser immunity 
that might favor the probability of developing 
first line ART treatment failure. 
The finding of our study on baseline 
functional status supports the findings in Debre 
Markos, Bale Zone and Addis Ababa Hospitals, 
Ethiopia (9, 16, 21). Those patients with 
bedridden baseline functional status had 2.71 
times higher hazards when compared to working 
functional status (AHR=2.71 95% CI=1.33 to 
5.51, P=0.006). This could be due to the fact that 
patients became bedridden as a result of 
infectious diseases when their CD4 cell counts 
were low. 
Our findings showed that individuals who 
began ART regimen with low baseline under-
nutrition (BMI <18Kg/m2) had 3.78 times 
(AHR=3.78, 95% CI=1.99 to 7.17, P=0.001) and 
those patients who were in the advanced WHO 
clinical stages III & IV haa 2.02 times more 
hazards towards treatment failure when compared 
to those patients who were at WHO stage I or II 
(AHR=2.02, 95% CI=1.02 to 4.00, P=0.045), a 
greater risk of time to first line antiretroviral 
treatment failure. These results are supported by 
previous studies in Ethiopia and Mozambique 
(12, 14, 18, 21).  
Finding of this study found that poor drug 
adherence was one of the predictors that had a 
significant effect on time to first line 
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antiretroviral treatment failure. This finding is 
consistent with the studies done in Kenya, 
Gondar, Bale and Thailand (10,12,16, 17). This 
might be due to the fact that HIV care providers 
were unable to assess adherence accurately, 
although standardized adherence assessment may 
be even more useful.  
This study also found that high risk 
behaviors like substance use at initiation of ART 
had 2.94 times higher probability of ART 
treatment failure compared to those patients 
without history of substance use (AHR=2.94, 
95% CI=1.62 to 5.32, P=0.001). This finding was 
in line with a study done in an urban HIV/AIDS 
clinic in Addis Ababa, Ethiopia (7). This might be 
due to the fact that a person who has history of 
substance use has poor adherence to ART 
regimens, which in turn may lead to reduced CD4 
count. 
In conclusion, the overall median survival 
time was 21 months. Lack of disclosed HIV 
status to family members, history of opportunistic 
infection at initiation of ART, high risk behaviors 
like substance use, low baseline CD4 count of 
below 200cells/mm3, low baseline under- 
nutrition of BMI <18Kg/m2, advanced WHO 
clinical staging, bedridden baseline functional 
status and poor drug adherence were independent 
predictors of time to first line treatment failure. 
Therefore, preventive information and counseling 
that focus on high risk behaviors like history of 
substance use and lack of disclosure of their HIV 
status to their family members should be 
routinely provided to all adult living with HIV.  
The strengths of this study are the use of 
standard measurements and the inclusion of the 
most important predictors of first line ART 
treatment failure. Since this study was based on 
secondary data and excluded patients records with 
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